| ¿µ¹® | pelvic inflammatory disease | ÇÑ±Û | °ñ¹Ý¿°Áúȯ |
|---|---|---|---|
| ¼³¸í | °ñ¹ÝÁÖÀ§ÀÇ Àå±â¿¡ ¹ß»ýÇÏ´Â ¿°ÁõÀ» ¸»ÇÔ. ÁÖ·Î ¿©¼º¿¡¼ ¹ß»ýÇÏ¸ç ¿øÀÎÀº ÀÓ±Õ(gonococcus)°ú ºñÀÓ±Õ¿¡ ÀÇÇÑ °¨¿°(non-gonorrheal infection)¿¡ ÀÇÇÑ´Ù. Áõ»óÀº Ãʱ⿡´Â ÁúºÐºñ¹°, ÇϺ¹ºÎµ¿Åë, ¿©¼ºÀÇ »ý½Ä±âºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¾ÐÅë, ¿ù°æÅë, ¿ù°æ·®ÀÇ Áõ°¡ µîÀÌ´Ù. ÀÏÂï Ä¡·áÇØ¾ß Çϸç, °è¼ÓÀûÀ¸·Î º´ÀÌ Áö¼Ó½Ã ¿©¼ºÀÇ ºÒÀÓÀÇ ¿øÀÎÀÌ µÈ´Ù. ÈÄÁø±¹¿¡¼´Â °¡Àå ¸¹Àº ¿©¼ººÒÀÓÀÇ ¿øÀÎÀ̱⵵ ÇÔ. Ä¡·á´Â Ç×»ýÁ¦ÀÇ Åõ¿©ÀÌ´Ù. |
||
| ¿µ¹® | chronic lymphocytic leukemia | ÇÑ±Û | ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´ |
|---|---|---|---|
| ¼³¸í | ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀÎ »óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐȼ¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀÎ ÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀÎ ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ ã¾Æ¿À°Ô µÈ´Ù. µû¶ó¼ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇÏ´Â °ñ¼ö Á¶Á÷¿¡¼´Â ÀÌ·± ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù. ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼¾ç¿¡¼´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼´Â °ÅÀÇ Ã£¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ¸ç ´ë°³ Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ ÈÇпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù. |
||
| ¿µ¹® | chronic obstructive pulmonary disease | ÇÑ±Û | ¸¸¼ºÆó¼âÆóº´ |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö õ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù. ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í ÀÌ·Î ÀÎÇØ¼ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀÌ Çª¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³´Ù. Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇÏ°Ô ÆìÁö´Â °ÍÀ» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù. ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀÎ Æó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | chronic active hepatitis | ÇÑ±Û | ¸¸¼ºÈ°µ¿°£¿° |
|---|---|---|---|
| ¼³¸í | BÇü °£¿°À̳ª ºñAÇü£ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Ư¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀÇ Ä§À±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ Ȳ´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈÁõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù. |
||
| ¿µ¹® | inflammatory bowel disease | ÇÑ±Û | ¿°Áõ¼ºÃ¢ÀÚº´ |
|---|---|---|---|
| ¼³¸í | À§Àå°üÀ» ħ¹üÇÏ´Â Á¤È®ÇÑ ¿øÀÎÀÌ ¹àÇôÁöÁö ¾ÊÀº ¸¸¼ºÀûÀÎ ¿°Áõ¼º ÁúȯÀ» ¸»ÇÑ´Ù. Å©°Ô ¡®±Ë¾ç¼º ´ëÀå¿°¡¯(ulcerative colitis)°ú ¡®Å©·Ðº´¡¯(Crohn's disease)ÀÇ µÎ Á¾·ù·Î ±¸ºÐµÈ´Ù. ¹éÀÎ, À¯ÅÂÀο¡ ¸¹°í ÈæÀÎÀ̳ª µ¿¾çÀο¡´Â µå¹°Áö¸¸ µ¿¾çÀο¡¼ Á¡Â÷ Áõ°¡Ãß¼¼¿¡ ÀÖ´Ù. È£¹ß¿¬·ÉÀº 15~35¼¼ »çÀÌÀÌ´Ù. Áõ»óÀº ¡®±Ë¾ç¼º ´ëÀå¿°¡¯ÀÇ °æ¿ì, ¼³»ç(Ç÷º¯ ¹× Á¡¾×º¯), µÚ¹«Á÷, º¹Åë, º¹ºÎ¾ÐÅë, üÁß°¨¼Ò µîÀÌ ÁÖ·Î ³ªÅ¸³ª¸ç ¡®Å©·Ðº´¡¯¿¡¼´Â ¼³»ç¿Í üÁß°¨¼Ò, ¿ìÇϺ¹ºÎ Á¾·ù, Ç×¹®ÁÖÀ§ ÀÌ»ó, º¹ºÎ¾ÐÅë µîÀÌ ³ªÅ¸³´Ù. Áø´ÜÀº º´·Â°ú ¹æ»ç¼±ÇÐÀû °Ë»ç, Á÷Àå°æ ¹× ´ëÀå ³»½Ã°æ°Ë»ç, Á÷Àå ¹× ´ëÀåÀÇ Á¶Á÷°Ë»ç·Î Çϸç Ä¡·á´Â ³»°úÀûÀÎ Ä¡·á°¡ ¿øÄ¢À̳ª ³»°úÀû Ä¡·á¿¡ µèÁö ¾Ê°Å³ª ÇÕº´ÁõÀÌ »ý±æ °æ¿ì¿¡´Â ¿Ü°úÀû Ä¡·á¸¦ ½ÃÇàÇÑ´Ù. ¡®±Ë¾ç¼º ´ëÀå¿°¡¯ÀÇ °æ¿ì¿¡´Â ¡®´ëÀå¾Ï¡¯À» ¿¹¹æÇϱâ À§Çؼ ¿Ü°úÀû Ä¡·á¸¦ Çϱ⵵ ÇÑ´Ù. ¡®±Ë¾ç¼º ´ëÀå¿°¡¯°ú ¡®Å©·Ð º´¡¯¿Ü¿¡ ¿°Áõ¼º âÀÚº´¿¡ ¼ÓÇÏ´Â ¡®º£Ã¼Æ® º´¡¯Àº Àç¹ß¼º ±¸°³» ±Ë¾ç, ÇǺΠº´º¯, ¾È±¸ºÎ ¿°Áõ, ¿ÜÀ½ºÎ ±Ë¾ç, °üÀý¿° Áõ»ó, À§Ã¢ÀÚ°ü Áõ»ó(º¹Åë, ÀåÃâÇ÷), ºÎ°íȯ¿° µîÀÇ Áõ»óÀ» ³ªÅ¸³»´Âµ¥ Áø´Ü°ú Ä¡·á´Â ¡®±Ë¾ç¼º ´ëÀå¿°¡¯, ¡®Å©·Ð º´¡¯°ú ºñ½ÁÇÏ´Ù. |
||
| CIDP | chronic idiopathic polyradiculopathy; chronic inflammatory demyelinating polyradiculoneuropathy |
|---|---|
| CIDP | Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy |
| CR-DIP | chronic relapsing demyelinating inflammatory polyneuropathy |
| CIP | chronic idiopathic polyradiculoneuropathy; chronic intestinal pseudo-obstruction; Collection de l'In... |
| IDP | immunodiffusion procedure; inflammatory demyelinating neuropathy; initial dose period; inosine dipho... |
| CIDP | Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
|---|---|
| CIDP | Chronic Inflammatory Demyelinating Neuropathy |
| CIDP | Chronic Inflammatory Demyelinating Polyneuropathy |
| AIDP | Acute inflammatory demyelinating polyneuropathy |
| CIBD | Chronic inflammatory bowel disease |
| chronic inflammatory demyelinating polyneuropathy | An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone. (05 Mar 2000) |
|---|---|
| polyradiculoneuropathy | Coexisting polyradiculopathy and polyneuropathy. (05 Mar 2000) |
| chronic inflammatory polyneuropathy | <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response. The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable. Origin: Gr. Pathos = disease (27 Sep 1997) |
| acute demyelinating polyneuropathy | <neurology> A neurologic condition. Synonym: Guillain-Barre syndrome. Origin: Gr. Pathos = disease (27 Sep 1997) |
| segmental demyelinating polyneuropathy | A type of polyneuropathy in which almost solely the peripheral nerve myelin is affected; can be both familial (e.g., Charcot-Marie Tooth disease, type 1), or acquired (e.g., Guillain-Barre syndrome); on motor nerve conduction studies, manifested as conduction slowing or block. Synonym: segmental demyelinating polyneuropathy. (05 Mar 2000) |
| demyelinating disease | Diseases in which the myelin sheath of nerves is destroyed and that often have an autoimmune component. Examples are multiple sclerosis, acute disseminated encephalomyelitis (a complication of acute viral infection), experimental allergic encephalomyelitis, Guillain-Barre syndrome. (18 Nov 1997) |
| demyelinating diseases | Any condition characterised by the destruction of myelin and extensive loss of the myelin sheaths of the nerve fibres. It affects both the central and peripheral nervous systems. Its aetiology is at present unknown. (12 Dec 1998) |
| demyelinating encephalopathy | Extensive idiopathic loss of myelin sheaths in the brain, as occurs in leukodystrophy. (05 Mar 2000) |
| demyelinating polyneuropathy | A type of polyneuropathy in which almost solely the peripheral nerve myelin is affected; can be both familial (e.g., Charcot-Marie Tooth disease, type 1), or acquired (e.g., Guillain-Barre syndrome); on motor nerve conduction studies, manifested as conduction slowing or block. Synonym: segmental demyelinating polyneuropathy. (05 Mar 2000) |
| acute inflammatory polyneuropathy | <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin. The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months. Synonym: Guillain-Barre syndrome (12 Jul 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|